← Back to Search

Neuromodulation

Brain Zapping for ADHD

N/A
Recruiting
Led By Joan Camprodon, MD, PhD, MPH
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and female subjects 18-66 years of age
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change before and after stimulation on each of the three visits, average 2-6 weeks
Awards & highlights

Study Summary

This trial will use brain zapping to study the effects of tDCS on executive function and inhibitory control in patients with ADHD compared to healthy controls.

Who is the study for?
This trial is for English-speaking adults aged 18-66 with ADHD, diagnosed per DSM-5 criteria. Participants can be on stimulants but must stop them two days before each study visit. Excluded are those with unstable psychiatric conditions, metal implants in the head/neck, brain stimulators, or who are pregnant/nursing.Check my eligibility
What is being tested?
The study tests how transcranial direct current stimulation (tDCS) affects executive function and self-control in adults with ADHD compared to healthy individuals. It examines the temporary changes caused by this non-invasive brain stimulation technique.See study design
What are the potential side effects?
Potential side effects of tDCS may include discomfort at the electrode site, itching or tingling during stimulation, headache, fatigue, nausea or dizziness. Serious risks like seizures are rare but possible in susceptible individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 66 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change before and after stimulation on each of the three visits, average 2-6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change before and after stimulation on each of the three visits, average 2-6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Accuracy and Reaction Time in Attention and Working Memory
Change in Accuracy and Reaction Time in Inhibition/Decision Making
Secondary outcome measures
Amplitude of Encephalogram (EEG) Event Related Potentials

Side effects data

From 2021 Phase 2 & 3 trial • 160 Patients • NCT02483468
2%
skin irritation
2%
Car accident
100%
80%
60%
40%
20%
0%
Study treatment Arm
tDCS (Active)
tDCS (Sham)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Healthy ControlExperimental Treatment1 Intervention
Volunteers without Neuropsychiatric Disorders.
Group II: ADHDExperimental Treatment1 Intervention
Patients with ADHD.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Direct Current Stimulation
2014
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,924 Previous Clinical Trials
13,193,303 Total Patients Enrolled
59 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
8,419 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Joan Camprodon, MD, PhD, MPHPrincipal InvestigatorMassachusetts General Hospital
5 Previous Clinical Trials
864 Total Patients Enrolled
2 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
704 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Media Library

tDCS (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT04175028 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Healthy Control, ADHD
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: tDCS Highlights & Side Effects. Trial Name: NCT04175028 — N/A
tDCS (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04175028 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Patient Testimony for trial: Trial Name: NCT04175028 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the eligibility criteria for this clinical trial extend to people below 30 years of age?

"Based on the enrolment criteria, this medical trial is open to individuals aged 18–66. There are 108 studies for those under 18 and 35 studies for seniors above 65 years of age."

Answered by AI

Am I eligible to enroll in this experiment?

"This clinical study is recruiting 120 men and women between the ages of 18-66 who are diagnosed with Attention Deficit Disorder (ADD). To qualify, participants must meet these criteria: abide by DSM-5 guidelines for diagnosis, display both inattentive or impulsive/hyperactive traits before age 12, discontinue stimulant medication use two days prior to testing under physician guidance if applicable, be capable of speaking English fluently."

Answered by AI

Is the research project currently recruiting participants?

"Reportedly, this clinical trial is currently recruiting participants. The initial announcement was published on September 1st 2014 and it has been recently updated on July 21st 2022."

Answered by AI

How many participants are being observed in this clinical research?

"Correct. The info on clinicaltrials.gov alludes to the fact that this research is actively searching for participants; it was initially posted in September 2014 and last modified in July 2022. Altogether, 120 individuals are needed at a single medical facility."

Answered by AI

Who else is applying?

What state do they live in?
Massachusetts
What site did they apply to?
Massachusetts General Hospital
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
2

Why did patients apply to this trial?

Looking for new treatment s.
PatientReceived 2+ prior treatments
~5 spots leftby Sep 2024